Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 131 clinical trials
Featured trial
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease

A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease

transplant conditioning
stem cell transplantation
bone marrow transplant
nutritional supplement
stem cell transplant
  • 322 views
  • 08 Dec, 2020
  • 1 location
Featured trial
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Background: Peripheral blood stem cell transplantation procedures are used for people with sickle cell disease. Researchers want to improve the success and reduce the complications for these procedures. This might allow more people to have a transplant. Objective: To see if a new transplant regime is effective, safe and well …

red blood cell disorder
cell transplantation
stroke
sickle cell disease
  • 83 views
  • 22 Dec, 2020
  • 1 location
Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

adolescent participants with steroid-refractory acute graft-versus-host disease (SR-aGvHD) at Day 28.

  • 0 views
  • 14 Dec, 2021
  • 17 locations
Fecal Microbiota Transplantation in aGvHD After ASCT

Acute graft-versus-host-disease (aGvHD) is a typical complication after allogeneic hematopoetic stem cell transplantation (ASCT). About 30-60% of patients after ASCT are affected by aGvHD, which

  • 0 views
  • 23 Apr, 2022
  • 1 location
Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD

Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation. The recognized first-line treatment for grade 3-4

  • 0 views
  • 02 Sep, 2021
  • 1 location
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (2002)

-Refractory acute Graft-Versus-Host Disease (SR-aGVHD). The primary hypothesis is that T-Guard treatment will improve the Day 28 complete response (CR) rate in patients with Grades III and IV SR-aGVHD

  • 0 views
  • 10 May, 2022
  • 5 locations
Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation

The purpose of this study is to determine the response and toxicity rate of two different dosages (Individualized dosage VS. fixed dosage) of ATG as a prophylaxis for acute GVHD in

  • 0 views
  • 21 Dec, 2021
  • 1 location
Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation

The purpose of this study is to determine the response and toxicity rate of two different dosages (Individualized dosage VS. fixed dosage) of ATG as a prophylaxis for acute GVHD in

  • 0 views
  • 24 Mar, 2022
  • 1 location
Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT

bladder is also considered to be one of the immune attacked organs in acute graft-versus-host disease (aGVHD). The classic treatments for HC include hydration, alkalization, and bladder irrigation

hematologic disorders
acute graft-versus-host disease
hemorrhagic cystitis
graft versus host disease
antiviral agents
  • 1 views
  • 18 Sep, 2021
  • 1 location
Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS

An "intention-to-treat" study to evaluate the impact of allogeneic HSCT with Total Marrow and Lymphoid irradiation (TMLI), followed by Treg/Tcon adoptive immunotherapy, on overall survival in patients affected by Myelodysplastic Syndrome (MDS), according to IPSS-R.

  • 0 views
  • 27 Mar, 2021
  • 1 location